TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients-Reference-Cited by-同舟云学术

TC > 0.05 as a Pharmacokinetic Parameter of Paclitaxel for Therapeutic Efficacy and Toxicity in Cancer Patients

Published:2018-07-31 Issue:3 Volume:13 Page:341-347
ISSN:1574-8928
Container-title:Recent Patents on Anti-Cancer Drug Discovery
language:en
Short-container-title:PRA

Author:

Xin D.S.¹,Zhou L.²,Li C.Z.²,Zhang S.Q.³,Huang H.Q.⁴,Qiu G.D.¹,Lin L.F.¹,She Y.Q.¹,Zheng J.T.¹,Chen C.¹,Fang L.¹,Chen Z.S.⁵,Zhang S.Y.¹

Affiliation:

1. Department of Pharmacy, Cancer Hospital of Shantou University Medical College, Raoping Rd, Shantou 515041, Guangdong, China

2. Department of Gynecologic Oncology, Cancer Hospital of Shantou University Medical College, Raoping Rd, Shantou 515041, Guangdong, China

3. Medical Oncology, Cancer Hospital of Shantou University Medical College, Raoping Rd, Shantou, Guangdong, 515041, China

4. Department of Ultrasound, Cancer Hospital of Shantou University Medical College, Raoping Rd, Shantou 515041, Guangdong, China

5. Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John`s University, 8000 Utopia Parkway, Queens, NY 11439, United States

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology (medical),Cancer Research,Drug Discovery,Oncology,General Medicine

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Paclitaxel therapeutic drug monitoring - International association of therapeutic drug monitoring and clinical toxicology recommendations;European Journal of Cancer;2024-05

2. The correlation between paclitaxel chemotoxicity and the plasma albumin level in cancer patients;Journal of Clinical Pharmacy and Therapeutics;2022-11-03

3. Paclitaxel exposure-toxicity analysis reveals a pharmacokinetic determinant for dose-limiting neutropenia in East-Asian solid tumor patients: results from two prospective, phase II studies;Cancer Chemotherapy and Pharmacology;2022-08-03

4. Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer;Drugs;2021-12-11

5. Paclitaxel-Containing Nano-Apoliposomes Attenuate the Growth and Epithelial-Mesenchymal Transition of Cisplatin-Resistant Nasopharyngeal Carcinoma Cells;Science of Advanced Materials;2021-09-01